Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 3:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 308 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Moxifloxacin Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Electrocardiogram Effects and Pharmacokinetics of Ferumoxytol in Healthy Men and Women

NCT00360425
View directory record Official record
Conditions
Anemia
Interventions
ferumoxytol, moxifloxacin, placebo
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 14, 2026, 3:11 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Evaluation of Energy Drinks on Electrocardiographic, Vascular and Hematologic Parameters in Healthy Volunteers

NCT03021616
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
energy drink, Moxifloxacin 400mg, Placebo
Other
Lead sponsor
David Grant U.S. Air Force Medical Center
Federal
Eligibility
18 Years to 40 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Travis Air Force Base, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Oct 14, 2026, 3:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of The Effects Of SB 480848 (Darapladib) On The Electrical Conduction Of The Heart

NCT00411073
View directory record Official record
Conditions
Atherosclerosis
Interventions
Darapladib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 28, 2016 · Synced Oct 14, 2026, 3:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare the Effect on Heart Rhythm of 3 Days of GSK189075, Placebo, or Moxifloxacin in Healthy Adults

NCT00532610
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
Interventions
GSK189075
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Oct 14, 2026, 3:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac Repolarization

NCT01874561
View directory record Official record
Conditions
Cardiac Conduction and Repolarization
Interventions
Custirsen, Placebo, Moxifloxacin
Drug
Lead sponsor
Achieve Life Sciences
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2016 · Synced Oct 14, 2026, 3:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Tafenoquine Thorough QTc Study in Healthy Subjects

NCT01928914
View directory record Official record
Conditions
Malaria, Vivax
Interventions
Tafenoquine 300mg, Tafenoquine 600mg, Tafenoquine 1200mg, moxifloxacin, Placebo for Tafenoquine, Placebo for moxifloxaxin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Culver City, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 14, 2026, 3:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Two-Part Phase 1 Study to Investigate the Safety and Tolerability of Supratherapeutic Dose of Zanubrutinib and Effect of Zanubrutinib on Cardiac Repolarization in Healthy Subjects

NCT03432884
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BGB-3111, Placebo, Moxifloxacin
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Oct 14, 2026, 3:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine the Effect of BMS-791325 on the ECG QTcF Interval in Healthy Subjects

NCT02084953
View directory record Official record
Conditions
Hepatitis C
Interventions
BMS-791325, Moxifloxacin, Placebo matching BMS-791325
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 49 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2014 · Synced Oct 14, 2026, 3:11 PM EDT
Completed No phase listed Observational Results available

A 6-month Observational Study on Combined Oral Contraceptives and Body Weight in Pre-Menopausal Women With Overweight or Obesity

NCT05061472
View directory record Official record
Conditions
Contraceptive Usage, Overweight or Obesity, Body Weight Changes, Appetitive Behavior, Eating Behavior
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
20 participants
Timeline
2022 – 2023
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 14, 2026, 3:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of IV ACHN-490 Injection on the QT/QTc Interval in Healthy Volunteers

NCT01514929
View directory record Official record
Conditions
Cardiac Effects in Normal Healthy Volunteers
Interventions
ACHN-490 Injection, Moxifloxacin, Placebo
Drug
Lead sponsor
Achaogen, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 9, 2012 · Synced Oct 14, 2026, 3:11 PM EDT
Suspended Phase 1 Interventional Accepts healthy volunteers

Determine the Effects of C-administration of AZD7325 and an Oral Contraceptive in Healthy Female Subjects

NCT00901290
View directory record Official record
Conditions
Pharmacokinetics
Interventions
monophasic oral contraceptive, AZD7325
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2010 · Synced Oct 14, 2026, 3:11 PM EDT
Completed Phase 4 Interventional Results available

Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery

NCT00870103
View directory record Official record
Conditions
Cataract
Interventions
Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2010 · Synced Oct 14, 2026, 3:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization)

NCT00708903
View directory record Official record
Conditions
Breast Cancer
Interventions
neratinib, Placebo, Moxifloxacin
Drug · Other
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated May 14, 2012 · Synced Oct 14, 2026, 3:11 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active Comparators

NCT00703313
View directory record Official record
Conditions
Healthy
Interventions
1.5% levofloxacin ophthalmic solution, 0.5% moxifloxacin hydrochloride ophthalmic solution, 0.3% gatifloxacin ophthalmic solution
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2009 · Synced Oct 14, 2026, 3:11 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Side Effect Profiles of Brand Name Versus Generic Oral Contraceptives

NCT00775190
View directory record Official record
Conditions
Contraception
Interventions
ortho tricyclen, Trinessa
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 14, 2026, 3:11 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis

NCT00396084
View directory record Official record
Conditions
Tuberculosis
Interventions
Gatifloxacin, Isoniazid, Levofloxacin, Linezolid, Moxifloxacin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 8, 2018 · Synced Oct 14, 2026, 3:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants

NCT04172987
View directory record Official record
Conditions
Healthy
Interventions
Tirzepatide, EE/NGM
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Oct 14, 2026, 3:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of ALKS 5461 on QT Intervals in Healthy Volunteers

NCT02479308
View directory record Official record
Conditions
Healthy
Interventions
Moxifloxacin, ALKS 5461, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 23, 2015 · Synced Oct 14, 2026, 3:11 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of AzaSite Versus Vigamox in the Tears of Healthy Volunteers

NCT00575367
View directory record Official record
Conditions
Bacterial Infections, Eye Infections
Interventions
AzaSite (azithromycin ophthalmic solution), Vigamox (moxifloxacin hydrochloride ophthalmic solution)
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2011 · Synced Oct 14, 2026, 3:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

ANX-188 Thorough QT/QTc Study in Healthy Volunteers

NCT01790087
View directory record Official record
Conditions
Healthy
Interventions
ANX-188 Therapeutic Dose, ANX-188 Supratherapeutic dose, Saline, Moxifloxacin
Drug
Lead sponsor
Mast Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Oct 14, 2026, 3:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Investigate the Effect of Balovaptan on the QTC Interval in Healthy Subjects

NCT03808298
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Balovaptan therapeutic dose Treatment A, Balovaptan supra-therapeutic dose Treatment B, Active control [moxifloxacin] on Day 2 Treatment C, Active control [Moxifloxacin] on Day 15 Treatment D, Placebo for Balovaptan Treatment C, Placebo for Balovaptan Treatment D, Placebo for Moxifloxacin Treatment A, Placebo for Moxifloxacin Treatment B, Moxifloxacin Treatment C, Placebo for Moxifloxacin Treatment C, Placebo for Moxifloxacin Treatment D, Moxifloxacin Treatment D
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 60 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2020 · Synced Oct 14, 2026, 3:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants to Study Electrocardiogram Effects

NCT03541564
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Healthy Participants
Interventions
BMS-986165, Moxifloxacin, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 14, 2026, 3:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effects of Tramadol Hydrochloride on Cardiac Repolarization in Healthy Participants

NCT02307864
View directory record Official record
Conditions
Healthy
Interventions
Tramadol HCl, Moxifloxacin 400 mg, Tramadol HCl Placebo, Moxifloxacin Placebo
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 14, 2026, 3:11 PM EDT
Terminated No phase listed Observational Results available

Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

NCT04518228
View directory record Official record
Conditions
HIV, Tuberculosis
Interventions
Bictegravir (BIC), Tenofovir alafenamide (TAF), Long-acting injectable formulation of cabotegravir (CAB LA), Dolutegravir (DTG), Atazanavir/ritonavir (ATV/r), Darunavir/ritonavir (DRV/r), Lopinavir/ritonavir (LPV/r), Cobicistat, Ritonavir, First-Line TB Treatment, Second-Line TB Treatment, Doravirine (DOR)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 14, 2026, 3:11 PM EDT